Company intelligence / Profile preview
MolGenie
Stuttgart, Baden-Württemberg, Germanymolgenie.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
MolGenie has developed novel small molecule inhibitors targeting SARS-CoV-2 Mpro, showing greater potency than nirmatrelvir (PAXLOVID), with compounds effective against Omicron and Delta variants. Programs have completed in vitro antiviral and in vivo proof-of-concept studies. No clinical trials have been initiated yet.
- Therapeutic areas
- Infectious DiseasesOther
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Anixa Biosciences (COVID-19 antiviral drug discovery)OntoChem (technology transfer and collaboration)
Beyond the preview
Go deeper on MolGenie.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MolGenie.